Further, conflicting evidence has indicated similarities with respect to drug sensitivity and outcome between individuals with breast cancers harbouring BRCA1 mutations and those with promoter methylation [83, 101, 110–114]. This evidence concerns the gene BRCA1 and breast cancer.